A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look ...

Don't bet the farm on much relief. Novo Nordisk, maker of Ozempic and Wegovy, has been charging Americans outlandish prices for these blockbusters. Wegovy's list price in the U.S. is over $1,300 for a ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, ...

A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

Jim Cramer’s appearance on Squawk on the Street aired on January 17th covered a […] Medicare seeks to negotiate prices on 15 drugs, including Novo Nordisk's (NVO) GLP-1 weight-loss drugs Ozempic and ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

In a healthcare market brimming with potential, DarioHealth Corp. (Nasdaq: DRIO)* is quietly emerging as a standout player, combining cutting-edge technology with proven outcomes. Looking at recent ...